FY2025 Earnings Estimate for AbbVie Inc. Issued By William Blair (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Equities researchers at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note issued to investors on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the company will earn $11.86 per share for the year, down from their prior estimate of $12.27. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $11.17 per share.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, February 2nd. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.76 by $0.03. AbbVie had a return on equity of 162.28% and a net margin of 8.95%. The firm had revenue of $14.30 billion for the quarter, compared to analysts’ expectations of $14.02 billion. During the same period last year, the firm earned $3.60 EPS. The firm’s revenue was down 5.4% compared to the same quarter last year.

Several other research firms have also weighed in on ABBV. BMO Capital Markets raised their price objective on AbbVie from $187.00 to $195.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Barclays lifted their target price on AbbVie from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 27th. Truist Financial boosted their target price on AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th. Raymond James upped their price objective on AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Finally, Guggenheim raised their price objective on AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $177.43.

AbbVie Stock Up 0.2 %

Shares of ABBV stock opened at $164.66 on Thursday. The stock has a market cap of $291.56 billion, a PE ratio of 60.32, a price-to-earnings-growth ratio of 2.09 and a beta of 0.58. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. The business’s fifty day moving average is $175.59 and its 200-day moving average is $159.97. AbbVie has a 1 year low of $130.96 and a 1 year high of $182.89.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently modified their holdings of ABBV. Tower Wealth Partners Inc. acquired a new position in AbbVie in the first quarter valued at $222,000. Naviter Wealth LLC raised its holdings in shares of AbbVie by 18.6% during the first quarter. Naviter Wealth LLC now owns 12,979 shares of the company’s stock valued at $2,363,000 after purchasing an additional 2,034 shares during the period. West Oak Capital LLC raised its holdings in shares of AbbVie by 1.6% during the first quarter. West Oak Capital LLC now owns 9,546 shares of the company’s stock valued at $1,738,000 after purchasing an additional 150 shares during the period. Capital Advisors Ltd. LLC raised its holdings in shares of AbbVie by 3.0% during the first quarter. Capital Advisors Ltd. LLC now owns 4,398 shares of the company’s stock valued at $801,000 after purchasing an additional 128 shares during the period. Finally, Narus Financial Partners LLC raised its holdings in shares of AbbVie by 6.6% in the 1st quarter. Narus Financial Partners LLC now owns 1,999 shares of the company’s stock worth $364,000 after acquiring an additional 124 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 21,082 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the completion of the sale, the executive vice president now directly owns 55,903 shares in the company, valued at $9,855,698.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Nicholas Donoghoe sold 21,082 shares of AbbVie stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total value of $3,716,756.60. Following the completion of the sale, the executive vice president now directly owns 55,903 shares in the company, valued at $9,855,698.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jeffrey Ryan Stewart sold 58,949 shares of AbbVie stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $178.79, for a total transaction of $10,539,491.71. Following the completion of the sale, the executive vice president now owns 60,941 shares of the company’s stock, valued at $10,895,641.39. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 383,324 shares of company stock worth $67,780,003. Company insiders own 0.25% of the company’s stock.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of 3.77%. The ex-dividend date is Friday, April 12th. AbbVie’s payout ratio is 227.11%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.